Neurology

GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for...

Xequel Bio Expands Leadership Team with Appointments of Dr. Michael J. Brubaker as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer

Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Michael Brubaker, Ph.D., Xequel Bio, Chief Scientific Officer “The addition...

Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)

Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global...

Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer’s Association International Conference (AAIC)

– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of OP-801 in comparison to TSPO-PET for...

Digital Health Technologies Market to Garner USD 68.89 Billion by 2029: Industry Analysis by Technology, Application, Types, Key Segment, Challenges and Future Growth Prospects

MELBOURNE, Australia, July 14, 2022 /PRNewswire/ -- A Qualitative Research Study accomplished by Data Bridge Market research's database of 350...

Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data

Quantitative biomarkers of demyelination can improve clinical trial design and accelerate development of disease-modifying therapeutics SAN FRANCISCO, July 14, 2022...

New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide

Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 14,...

error: Content is protected !!